Overview

A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer

Status:
Terminated
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This study proposed the comparison the overall survival, hematological toxicity, pain reduction score,PSA levels, tumor response, quality of life in two arms of HRPC patients from different parts of India.
Phase:
Phase 2
Details
Lead Sponsor:
Cadila Pharnmaceuticals
Treatments:
Docetaxel
Hormones